Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Bully Pulpit in Action: Cipro and Zevalin

This article was originally published in RPM Report

Executive Summary

Former HHS Secretary Thompson's negotiation of a price discount on Bayer's antibiotic Cipro during the anthrax scare of 2001 is everybody's favorite example of price negotiation in action. The real lesson of that case, though, is that negotiation can pay off for manufacturers. For a less rosy example, consider Biogen Idec's experience with Zevalin.

You may also be interested in...



Favorable Drug Pricing Language In COVID-19 Government Contracts May Backfire for Industry

Pharma has won pricing battles during the pandemic, but doesn’t seem to be winning war as senators on both sides of the aisle question how some drug companies were able to skirt controversial intellectual property ownership issues in COVID-19 drug and vaccine agreements with the US government. IP experts say the biggest harm to the government from the contracting language may not be the pricing concerns but the government’s ability to share leanings from the partnerships with other coronavirus development programs.

Dendreon vs. CMS:Controversy Is Bigger Than One Product

It appeared as though the controversy over the level of efficacy and benefit from the prostate cancer immunotherapy Provenge ended when the drug was approved by FDA at the end of April. The FDA approval may have just been the halfway point in the product's route through government agencies to the commercial market. Now Medicare is questioning whether the government should pay for the new therapy. The CMS decision is just as important to the biopharmaceutical industry as it is to Dendreon.

Putting the Bully in the Bully Pulpit: The Democrats' Plan to Cut Drug Prices

Legislation to force price negotiation under Medicare Part D is likely to end in a stalemate. But manufacturers can't afford to relax: the Democrats plan to turn up the pressure even if a law never passes. First they will compare Part D prices to other benchmarks. Then the bullying begins.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS080224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel